BioNTech (NASDAQ:BNTX) Raised to “Strong-Buy” at Hsbc Global Res

Hsbc Global Res upgraded shares of BioNTech (NASDAQ:BNTX) from a hold rating to a strong-buy rating in a research note published on Friday morning, Zacks.com reports.

Several other research analysts have also recently issued reports on the company. TD Cowen upped their price target on BioNTech from $95.00 to $98.00 and gave the company a hold rating in a report on Tuesday, May 7th. BMO Capital Markets reduced their target price on BioNTech from $123.00 to $122.00 and set an outperform rating for the company in a report on Tuesday, May 7th. HC Wainwright reissued a buy rating and issued a $113.00 price target on shares of BioNTech in a research note on Thursday, August 1st. Evercore ISI assumed coverage on shares of BioNTech in a research note on Tuesday, May 14th. They set an inline rating and a $100.00 price objective for the company. Finally, HSBC upgraded shares of BioNTech from a hold rating to a buy rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of Hold and an average price target of $110.40.

BioNTech Price Performance

BNTX stock traded up $1.14 during trading hours on Friday, hitting $79.50. 740,558 shares of the stock traded hands, compared to its average volume of 701,449. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. The stock has a 50-day simple moving average of $87.74 and a 200 day simple moving average of $90.63. BioNTech has a one year low of $76.53 and a one year high of $125.83. The company has a market cap of $18.90 billion, a P/E ratio of 159.00 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The business had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. During the same quarter last year, the business posted ($0.86) EPS. The business’s revenue for the quarter was down 23.3% on a year-over-year basis. Equities analysts forecast that BioNTech will post -2.04 earnings per share for the current year.

Institutional Investors Weigh In On BioNTech

A number of institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC grew its stake in shares of BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after buying an additional 150 shares in the last quarter. CWM LLC grew its position in BioNTech by 657.6% in the fourth quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after acquiring an additional 217 shares in the last quarter. Frazier Financial Advisors LLC bought a new stake in BioNTech in the fourth quarter worth approximately $30,000. First Horizon Advisors Inc. acquired a new position in shares of BioNTech during the 4th quarter worth $38,000. Finally, Covestor Ltd raised its holdings in shares of BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.